Recent Performance and Investor Context Daiichi Sankyo Company (TSE:4568) has been drifting lower this year, even after solid revenue and profit growth. This has left the stock meaningfully below past ...
After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the ...
Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration ...
AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.
The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...
Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...
Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day December 15, ...
South Korea-based Lunit, a provider of AI for cancer diagnostics and precision oncology, has announced a deal with Japanese ...
Zacks Investment Research on MSN
CPRX vs. DSNKY: Which stock is the better value option?
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two companies is the ...
Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results